Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

In this study (n=490), switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide was not associated with loss of virological control at week 48 versus continued TDF (one patient in each group; non-inferiority demonstrated), with improvements in safety noted.

Source:

Lancet Gastroenterology and Hepatology